NetraMark’s Q3 Success with AI Clinical Trial Analytics
Company Announcements

NetraMark’s Q3 Success with AI Clinical Trial Analytics

Story Highlights

NetraMark Holdings (TSE:AIAI) has released an update.

NetraMark Holdings Inc., a leader in AI software for clinical trial analytics, has reported significant progress in Q3, including the full commercialization of its proprietary AI platform validated by a major pharmaceutical company. They’ve refined their market strategy to focus on CNS and Oncology sectors and have secured a substantial client with over $10B USD market cap, resulting in four contracts. NetraMark’s AI technology aims to mitigate the high failure rates of clinical trials in the pharmaceutical industry by improving decision-making and potentially saving millions in investment.

For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskNetraMark Appoints Oncology Expert P.J. Haley to Board
TipRanks Canadian Auto-Generated NewsdeskNetraMark Unveils New Suite to Revolutionize Clinical Trials
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App